scholarly journals Study of Tumor Cells in the G0 or G1 Nerve Growth State

2021 ◽  
pp. 223-260
Author(s):  
Ricardo Gobato ◽  
Abhijit Mitra

The cell cycle of such a subject has been thoroughly studied, yet here we are examining for the second time that we have entered a new phase; Biology always has new insights to show us. This data was amazing. This map is based on this beautiful circular pattern that we have identified as all the different stages of the cell cycle. Have a disease. When Placer and colleagues used the ccAF tool to analyze cell data for glioma tumors, we found that tumor cells were often in the G0 or G1 nerve growth state. With tumor aggression, fewer cells remain at rest in the G0 nerve state. This means that more cells are growing and growing in the tumor. Keywords: Cancer; Cells; Tissues; Tumors; Prevention; Prognosis; Diagnosis; Imaging; Screening, Treatment; Management

2021 ◽  
pp. 237-275
Author(s):  
Elena Locci ◽  
Silvia Raymond

The cell cycle of such a subject has been thoroughly studied, yet here we are examining for the second time that we have entered a new phase; Biology always has new insights to show us. This data was amazing. This map is based on this beautiful circular pattern that we have identified as all the different stages of the cell cycle. Have a disease. When Placer and colleagues used the ccAF tool to analyze cell data for glioma tumors, we found that tumor cells were often in the G0 or G1 nerve growth state. With tumor aggression, fewer cells remain at rest in the G0 nerve state. This means that more cells are growing and growing in the tumor. Keywords: Cancer; Cells; Tissues, Tumors; Prevention, Prognosis; Diagnosis; Imaging; Screening; Treatment; Management


2018 ◽  
Author(s):  
Ricardo Guimarães Amaral ◽  
Silvana Vieira Floresta Gomes ◽  
Ângelo Roberto Antoniolli ◽  
Maria Claudia dos Santos Luciano ◽  
Cláudia do Ó Pessoa ◽  
...  

AbstractThis work aimed to evaluate the cytotoxic potential against cancer cells of Passiflora genus plant species cultivated in Brazil and identify the mechanism of cytotoxicity induced by the most promising extract. Leaf extracts from 14 Passiflora (P.) species were obtained ASE and in vitro cytotoxicity evaluated against cancer cell lines using MTT assay at a single concentration of 50 μg/mL. Additionally, the IC50 of the P. alata (ELPA) leaf extracts was determined against both tumor (HCT-116, SF-295, OVACAR-8, and HL-60), and non-tumor cells (PBMC). The ELPA flavonoids were identified by HPLC-DAD and UHPLC-MS/MS. The morphological analyses used light and fluorescence microscopy, and cell cycle and DNA fragmentation analyses used flow cytometry to determine the mechanism of cell death induced by ELPA in HL-60. Among the Passiflora leaf extracts evaluated; ELPA stood out with high cytotoxic activity, followed by P. capsularis and P. quadrangulares with varying high and low cytotoxic activity. ELPA presented high cytotoxic potency in HL-60 (IC50 19.37 μg/mL), yet without cytotoxic activity against PBMC, suggesting selectivity for tumor cells. The cytotoxic activity of ELPA may well be linked to the presence of ten identified flavonoids. Cells treated with ELPA presented the hallmarks typical of apoptosis and necrosis, with cell cycle arrest in the G2/M phase. Conclusion: From among the studied species, ELPA presented greater cytotoxic activity, possibly a consequence of synergistic flavonoid action which induces cell death by apoptosis and necrosis.


2019 ◽  
Author(s):  
Sila Appak-Baskoy ◽  
lknur Kulcanay Sahin ◽  
Ozgun Teksoy ◽  
Mustafa Cengiz ◽  
Asuman Deveci Ozkan ◽  
...  

AbstractTreatment options to improve overall survival rate of prostate cancer patients are limited since tumor cells acquire resistance to the chemotherapeutic drugs. We aimed to determine anticancer effects of stone alkaline water (SAW) on PC-3 and DU-145 prostate adenocarcinoma cell lines. SAW was obtained by triturating high stones under vacuum at 3000 °C. High mineral and trace element containing fraction of SAW was used for the experiments. Viability of the tumor cells was analyzed using tetrazolium based WST-1 cell proliferation assay, cell cycle analysis was carried out with Propidum Iodide staining (Muse™ Cell Cycle Kit). Acridine Orange and Annexin V stainings were done to analyze the cellular morphology and to determine apoptosis. Tumor cell derived angiogenesis was analyzed with migration and tube formation assays. SAW treatment resulted in accumulation of cells at G0/G1 phase and inhibited tumor cell induced HUVEC tube formation and migration. SAW treatment significantly decreased viability of PC-3 and DU-145 prostate adenocarcinoma cells and induced apoptotic cell death. Intriguingly, treatment of the prostate cancer cells with SAW inhibited tumor cell derived angiogenesis. SAW may aid in treating prostate cancer and molecules important for SAW’s apoptotic and anti-angiogenic effects need to be determined.


2019 ◽  
Author(s):  
Shifeng Shi ◽  
Xin Huang ◽  
Xiao Ma ◽  
Xiaoyan Zhu ◽  
Qinxian Zhang

AbstractPurposeChemotherapy resistance of esophageal cancer is a key factor affecting the postoperative treatment of esophageal cancer. Among the media that transmit signals between cells, the exosomes secreted by tumor cells mediate information transmission between tumor cells, which can make sensitive cells obtain resistance. Although some cellular exosomes play an important role in tumor’s acquired drug resistance, the related action mechanism is still not explored specifically.MethodsTo elucidate this process, we constructed a cisplatin-resistant esophageal cancer cell line, and proved that exosomes conferring cellular resistance in esophageal cancer can promote cisplatin resistance in sensitive cells. Through high-throughput sequencing analysis of the exosome and of cells after stimulation by exosomes, we determined that the miRNA193 in exosomes conferring cellular resistance played a key role in sensitive cells acquiring resistance to cisplatin. In vitro experiments showed that miRNA193 can regulate the cell cycle of esophageal cancer cells and inhibit apoptosis, so that sensitive cells can acquire resistance to cisplatin. An in vivo experiment proved that miRNA193 can promote tumor proliferation through the exosomes, and provide sensitive cells with slight resistance to cisplatin.ResultsSmall RNA sequencing of exosomes showed that exosomes in drug-resistant cells have 189 up-regulated and 304 down-regulated miRNAs; transcriptome results showed that drug-resistant cells treated with drug-resistant cellular exosomes have 3446 high-expression and 1709 low-expression genes; correlation analysis showed that drug-resistant cellular exosomes mainly affect the drug resistance of sensitive cells through paths such as cytokine–cytokine receptor interaction, and the VEGF and Jak-STAT signaling pathways; miRNA193, one of the high-expression miRNAs in drug-resistant cellular exosomes, can promote drug resistance by removing cisplatin’s inhibition of the cell cycle of sensitive cells.ConclusionSensitive cells can become resistant to cisplatin through acquired drug-resistant cellular exosomes, and miRNA193 can make tumor cells acquire cisplatin resistance by regulating the cell cycle.


2020 ◽  
Author(s):  
Lin He ◽  
Biyuan Zhang ◽  
Yuhua Song ◽  
Haiji Wang

Abstract Background: Sialic acid-binding lectin (cSBL) specifically kills tumor cells rather than healthy cells. Glycopolymer-coated nanoparticles are selectively ingested by tumor cells because they can interact with the enriched carbohydrate receptors located on the surface of tumor cells. In this context, we synthesized cSBL-modified fructose-coated nanoparticles (LMFN) and cSBL-modified glucose-coated nanoparticles (LMGN) to investigate their anticancer activity in various molecular subtypes of breast cancer cell lines. Methods: The syntheses of fructose-coated nanoparticles and glucose-coated nanoparticles were based on the chemicals of 1,2:4,5-di- O -isopropylidene- β -d-fructopyranose and 1,2:4,5-di- O -isopropylidene- β -d-glucopyranose, respectively. The carbodiimide-based method was employed to synthesize LMFN and LMGN. The antitumor mechanism was explored by cell cycle analysis with flowcytometry and the antitumor activity was assessed by cytotoxicity assay and multiple drug effects analysis. Results: The cytotoxicity assay showed that LMFN had robust antitumor activity against all breast cancer phenotype cell lines whereas LMGN was rarely efficacious to against human epidermal growth factor receptor 2-positive/overexpression (HER2+/overexpression) breast cancer cells. The intrinsic reason for these findings was that the overexpression of fructose transporter, GLUT5, was observed in all breast cancer subtype cell lines but only a paucity of glucose transporter, GLUT1, was expressed in HER2+/overexpression breast cancer cell lines that dampened the uptake of LMGN to these cells. The cell cycle analysis indicated that the anticancer activity of LMFN was achieved by arresting cell cycle in S phase. The multiple drug effects analysis suggested the synergistic effect in the combinations of LMFN and tamoxifen to kill estrogen receptor+ breast cancer cells and LMFN and trastuzumab to kill HER2+/overexpressed breast cancer cells. Conclusion: Our work pinpoints that LMFN may be a new-onset selection for molecularly targeted therapy of breast cancers and paves the way for establishing its clinical application in the future.


Author(s):  
Sheng Li ◽  
Lina Wu ◽  
Hong Zhang ◽  
Xijuan Liu ◽  
Zilei Wang ◽  
...  

Hepatocellular carcinoma (HCC) is characterized by a high rate of incidence and recurrence, and resistance to chemotherapy may aggravate the poor prognosis of HCC patients. Sorafenib resistance is a conundrum to the treatment of advanced/recurrent HCC. Therefore, studies on the molecular pathogenesis of HCC and the resistance to sorafenib are of great interest. Here, we report that GINS1 was highly expressed in HCC tumors, associated with tumor grades, and predicted poor patient survival using Gene Expression Omnibus (GEO) databases exploration. Cell cycle, cell proliferation assay and in vivo xenograft mouse model indicated that knocking down GINS1 induced in G1/S phase cell cycle arrest and decreased tumor cells proliferation in vitro and in vivo. Spheroid formation assay results showed that GINS1 promoted the stem cell activity of HCC tumor cells. Furthermore, GEO database (GSE17112) analysis showed that HRAS oncogenic gene set was enriched in GINS1 high-expressed cancer cells, and quantitative real-time PCR, and Western blot results proved that GINS1 enhanced HCC progression through regulating HRAS signaling pathway. Moreover, knocking down endogenous GINS1 with shGINS1 increased the sensitivity of HCC cells to sorafenib, and restoring HRAS or stem associated pathway partly recovered the sorafenib resistance. Overall, the collective findings highlight GINS1 functions in hepatocarcinogenesis and sorafenib resistance, and indicate its potential use of GINS1 in drug-resistant HCC.


Author(s):  
Tatiane Renata Fagundes ◽  
Bruna Bortoleti ◽  
Priscila Camargo ◽  
Vírgínia Concato ◽  
Fernanda Tomiotto-Pellissier ◽  
...  

Background: Conventional therapies for breast cancer is still a challenge due to use of cytotoxic drugs not highly effective with major adverse effects. Thiohydantoins, are biologically active heterocyclic compounds reported by several biological activities, including anticarcinogenic properties, i.e., this work aimed to assess the use of thiohydantoin as a potential antitumor agent against MCF-7 breast cancer cells. Methods: MTT and neutral red assays were used to assess the possible cytotoxic activity of compounds against MCF-7 cells. Cell volume measurement and analysis were performed by flow cytometry, fluorescence analysis was carried out to determine patterns of cell death induced by thiohydantoins. Results: The treatment with micromolar doses of thiohydantoins promoted a decrease in the viability of MCF-7 breast tumor cells. Also were observed the increase in ROS and NO production, reduction in cell volume, loss of membrane integrity, mitochondrial depolarization, and increased fluorescence for annexin V and caspase-3. These findings indicate cell death by apoptosis and increased formation of autophagic vacuoles and stopping the cell cycle in the G1/ G0 phase. Conclusions: Our results indicate that thiohydantoins are cytotoxic to breast tumor cells, and this effect is linked to the increase in ROS production. This phenomenon changes tumorigenic pathways, that lead to a halt of the cell cycle in G1/G0, an important checkpoint for DNA errors, which may have altered the process by which cells produce energy, causing a decrease in mitochondrial viability and thus leading to the apoptotic process. Furthermore, the results indicate increased autophagy, a vital process linked to a decrease in lysosomal viability and considered as a cell death and tumor suppression mechanism.


2016 ◽  
Author(s):  
Maria Sokolova ◽  
Mikko Turunen ◽  
Oliver Mortusewicz ◽  
Teemu Kivioja ◽  
Patrick Herr ◽  
...  

AbstractTo identify cell cycle regulators that enable cancer cells to replicate DNA and divide in an unrestricted manner, we performed a parallel genome-wide RNAi screen in normal and cancer cell lines. In addition to many shared regulators, we found that tumor and normal cells are differentially sensitive to loss of the histone genes transcriptional regulator CASP8AP2. In cancer cells, loss of CASP8AP2 leads to a failure to synthesize sufficient amount of histones in the S-phase of the cell cycle, resulting in slowing of individual replication forks. Despite this, DNA replication fails to arrest, and tumor cells progress in an elongated S-phase that lasts several days, finally resulting in death of most of the affected cells. In contrast, depletion of CASP8AP2 in normal cells triggers a response that arrests viable cells in S-phase. The arrest is dependent on p53, and preceded by accumulation of markers of DNA damage, indicating that nucleosome depletion is sensed in normal cells via a DNA-damage-like response that is defective in tumor cells.


1972 ◽  
Vol 27 (12) ◽  
pp. 1547-1566 ◽  
Author(s):  
Manfred Von Ardenne

Basic to the proposed therapeutic usage of the difference in the in-vivo proliferation control between cancer and normal cells are the temporary selective increase in the proliferation rate and number of cancer cells in all kinds of tumors but without increase of the proliferative activity of normal cells. To further this aim, measurements of cellular kinetics are used, in connection with the glycolysis of different tumor tissues under saturation conditions, with the relationship between cancer cell cycle and glycolytic rate, or the local glucose level respectively, with the wide range of glucose concentrations in tumor regions which differ the conditions of supply, with the pO2-value critical for tumor growth (≈ 0.4 Torr), with the pO2-distribution in tumor tissues and the time distribution of cell cycles in human and animal cancerous tissues. From an approximative description of the cytostatic effects in different tumor regions and its validity limits it is estimated that the sensitivity towarts therapy is decreased to as low as one-tenth in poorly supplied tumor regions. These particular fractions of the tumor tissues determine the degree of tumor resistence. Additionally, from these considerations steps can be derived which could be important for multiplying the effect of the cytostatic attack on the critical tumor regions with poor supply conditions. These steps include: a) usage of combinations of cytostatic agents directed against all three sensitive phases of the cell cycle (S-G2-M); b) increase in blood glucose concentration to about 300 mg% for an optimum time span prior to the initiation of the main therapeutic process; c) increase in pO2 of the inspiration air to 320 or 400 Torr and in the degree of pO2 utilization by the use of specific pharmaceutic agents for the chosen time span preceding the main therapy; d) stimulation of tumor vascularization preceding the main therapy; e) decrease in the fraction of tumor cells utilizing glucose and O2 as a consequence of a post-therapy treatment 72 hours after the main therapy. The increase in the fraction of cells in a sensitive phase of the cell cycle is reached folowing synchronization after increasing the glucose concentration until saturation of the glycolytic capacity. Reasons are given, why the cytostatic attack has to be supplemented by other selective mechanisms which damage the tumor cell independent of the phase of the cell cycle. Such a mechanism is the lysosomal cytolytic chain reaction. Here, the death of tumor cells occurring during a sensitive phase of the cell cycle as a consequence of the cytostatic attack helps to damage cancer cells which are in the insensitive phase. A further mechanism of this kind is the immunological attack, which is also a component of multi-step cancer therapy


2012 ◽  
Vol 224 (03) ◽  
Author(s):  
F Wachter ◽  
M Grunert ◽  
I Jeremias ◽  
H Ehrhardt
Keyword(s):  

Sign in / Sign up

Export Citation Format

Share Document